Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL164
- Development stage
- Preclinical
- Lead developer
- Alector
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
AL164 (also known as AL064) is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate being developed by Alector for the treatment of neurodegenerative diseases, specifically tauopathies such as Alzheimer's disease. The drug is designed to target the MAPT gene, which encodes the Tau protein. In tauopathies, Tau protein aggregates into toxic neurofibrillary tangles that correlate with cognitive decline and neuronal loss. By utilizing the RNA interference (RNAi) pathway to knockdown Tau expression at the mRNA level, AL164 aims to reduce the overall burden of Tau pathology in the brain, potentially slowing or halting disease progression.
- Other names
- Tau-siRNA
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on AL164.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL164.